Pliant Therapeutics, Inc. (PLRX) Bundle
Understanding Pliant Therapeutics, Inc. (PLRX) Revenue Streams
Understanding Pliant Therapeutics, Inc. Revenue Streams
As of September 30, 2024, Pliant Therapeutics, Inc. has not generated any revenue from product sales. The company previously derived revenue from a Collaboration and License Agreement with Novartis, which was executed in 2019. This included an upfront license fee payment of $50 million and an additional $29 million upon the achievement of specified research and development milestones. However, Novartis terminated this agreement in February 2023, leading to a significant impact on revenue streams.
For the three months ended September 30, 2024, the reported revenue was $0, compared to $0 for the same period in 2023. For the nine months ended September 30, 2024, the revenue was $0 compared to $1.58 million for the nine months ended September 30, 2023, which was derived from research and development services prior to the termination of the Novartis Agreement.
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| Q3 2024 | $0 | 0% |
| Q3 2023 | $0 | 0% |
| 9M 2024 | $0 | –100% |
| 9M 2023 | $1.58 million | – |
The termination of the Novartis Agreement resulted in the loss of potential milestone and royalty payments, which previously contributed to revenue. The company is currently focused on research and development activities to advance its product candidates but does not expect to generate product sales revenue in the near future. As of September 30, 2024, the accumulated deficit stood at $660.3 million.
Overall, the significant changes in revenue streams indicate a shift in focus towards future development efforts, with the expectation of increased research and development expenses. For the nine months ended September 30, 2024, total operating expenses amounted to $175.045 million, compared to $138.688 million for the same period in 2023, reflecting an increase of $36.357 million.
| Expense Category | 9M 2024 (in thousands) | 9M 2023 (in thousands) | Change (in thousands) |
|---|---|---|---|
| Research and Development | $130,517 | $94,614 | $35,903 |
| General and Administrative | $44,528 | $44,074 | $454 |
| Total Operating Expenses | $175,045 | $138,688 | $36,357 |
The increase in research and development expenses was primarily driven by activities related to the BEACON-IPF study and increased employee-related costs attributed to headcount growth. Moving forward, the company anticipates continued investments in research and development activities as it seeks to advance its product candidates through clinical trials.
A Deep Dive into Pliant Therapeutics, Inc. (PLRX) Profitability
A Deep Dive into Pliant Therapeutics, Inc.'s Profitability
Gross Profit Margin: As of September 30, 2024, the company reported a revenue of $0, resulting in a gross profit margin of 0%.
Operating Profit Margin: The operating loss for the three months ended September 30, 2024, was ($62,014,000), with total operating expenses of ($62,014,000) for the same period, leading to an operating profit margin of 0%.
Net Profit Margin: The net loss for the three months ended September 30, 2024, was ($57,763,000), translating to a net profit margin of 0%.
Trends in Profitability Over Time
For the three months ended September 30, 2024, the net loss increased by $16,276,000 compared to the loss of ($41,487,000) for the same period in 2023. For the nine months ended September 30, 2024, the net loss was ($160,572,000), compared to ($120,227,000) for the same period in 2023, reflecting a trend of increasing losses.
Comparison of Profitability Ratios with Industry Averages
The company has not generated any revenue from product sales and relies on collaboration agreements for income. The average net profit margin in the biopharmaceutical industry is typically negative, reflecting high R&D costs similar to the company's current metrics.
Analysis of Operational Efficiency
The company’s research and development expenses for the three months ended September 30, 2024, were $47,754,000, compared to $32,339,000 in 2023, indicating increased operational costs. General and administrative expenses were $14,260,000 for the three months ended September 30, 2024, down from $15,346,000 in the previous year.
| Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating Expenses | ($62,014,000) | ($47,685,000) | ($14,329,000) |
| Net Loss | ($57,763,000) | ($41,487,000) | ($16,276,000) |
| Net Loss per Share | ($0.95) | ($0.70) | ($0.25) |
As of September 30, 2024, the accumulated deficit stood at ($660,320,000), with cash, cash equivalents, and short-term investments totaling $406,000,000 .
Debt vs. Equity: How Pliant Therapeutics, Inc. (PLRX) Finances Its Growth
Debt vs. Equity: How Pliant Therapeutics Finances Its Growth
Pliant Therapeutics, Inc. has a complex financial structure that relies on both debt and equity to fund its operations and growth. As of September 30, 2024, the company's total liabilities stood at $99.8 million, which primarily includes long-term debt of $30.1 million and current liabilities totaling $39.9 million.
Overview of the Company's Debt Levels
The company has both long-term and short-term debt. The long-term debt of $30.1 million is associated with an Amended Loan Agreement executed on March 11, 2024, which allows for borrowing up to $150 million. The current liabilities include accounts payable of $6.9 million, accrued research and development liabilities of $23.0 million, and accrued liabilities of $9.7 million.
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio is a critical measure of financial leverage. As of September 30, 2024, Pliant Therapeutics reported total stockholders' equity of $345.8 million. This results in a debt-to-equity ratio of approximately 0.29 ($30.1 million in debt / $345.8 million in equity). This ratio is below the industry average of approximately 0.5, indicating a conservative approach to leveraging debt for growth.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
In March 2024, the company entered into an Amended and Restated Loan and Security Agreement to increase its borrowing capacity. The interest rate on borrowings is set at the 1-month term Secured Overnight Financing Rate (SOFR) plus 5.25%, subject to a floor of 8.75%. The company’s credit ratings have not been specifically disclosed in the available data; however, the terms of the loan suggest a strong position in negotiations with lenders.
How the Company Balances Between Debt Financing and Equity Funding
Pliant Therapeutics has employed both equity and debt financing to support its growth initiatives. As of September 30, 2024, the company had 60,849,503 shares of common stock outstanding, with an additional paid-in capital of $1.0 billion. In January 2023, the company raised $270.3 million through a public offering, which significantly bolstered its equity position.
The table below summarizes Pliant Therapeutics' debt and equity structure as of September 30, 2024:
| Category | Amount (in millions) |
|---|---|
| Total Liabilities | $99.8 |
| Long-term Debt | $30.1 |
| Current Liabilities | $39.9 |
| Total Stockholders' Equity | $345.8 |
| Debt-to-Equity Ratio | 0.29 |
| Common Shares Outstanding | 60.8 million |
| Additional Paid-In Capital | $1,005.3 |
Assessing Pliant Therapeutics, Inc. (PLRX) Liquidity
Assessing Pliant Therapeutics, Inc. Liquidity
Current Ratio: As of September 30, 2024, the current assets were $406.0 million, while current liabilities totaled $39.9 million, resulting in a current ratio of approximately 10.2.
Quick Ratio: Given that the company has no inventory, the quick ratio is equivalent to the current ratio, remaining at 10.2.
Analysis of Working Capital Trends
Working capital, calculated as current assets minus current liabilities, stood at $366.1 million as of September 30, 2024. This indicates a substantial liquidity buffer, reflecting a strong ability to cover short-term obligations.
Cash Flow Statements Overview
| Cash Flow Category | Nine Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | $(107,841) | $(91,259) |
| Net Cash Provided by (Used in) Investing Activities | $101,208 | $(158,933) |
| Net Cash Provided by Financing Activities | $23,015 | $274,186 |
| Net Increase in Cash and Cash Equivalents | $16,382 | $23,994 |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company had $406.0 million in cash, cash equivalents, and short-term investments, which positions the company to fund anticipated operating expenses and capital expenditures for the next 12 months. The liquidity appears robust, although reliance on continued capital raises could pose a risk if market conditions change.
The company incurred a net loss of $(160.6 million) for the nine months ended September 30, 2024, compared to $(120.2 million) for the same period in 2023. This trend of increasing losses may necessitate additional financing to sustain operations.
Is Pliant Therapeutics, Inc. (PLRX) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis of the company focuses on key financial metrics that provide insight into its market position and investment potential.
Price-to-Earnings (P/E) Ratio
The company's P/E ratio is currently not applicable as it has not generated any revenue from product sales, resulting in a consistent net loss. For the three months ended September 30, 2024, the net loss was $57.8 million.
Price-to-Book (P/B) Ratio
The P/B ratio is calculated using the book value of equity. As of September 30, 2024, the total stockholders' equity was $345.8 million with 60,849,503 shares outstanding, resulting in a book value per share of approximately $5.68.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
As the company has not generated EBITDA due to operating losses, the EV/EBITDA ratio is also not applicable. The net loss for the nine months ended September 30, 2024, was $160.6 million.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated significantly. The stock reached a high of approximately $30.00 following a public offering in January 2023. However, the stock has faced downward pressure as the company reported increased losses.
Dividend Yield and Payout Ratios
The company does not pay dividends, and therefore the dividend yield is 0%. The payout ratio is also not applicable due to the absence of earnings.
Analyst Consensus on Stock Valuation
Analyst consensus generally recommends a 'Hold' rating, reflecting caution due to the company's ongoing losses and the lack of revenue generation. The average price target set by analysts is approximately $17.00.
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | Approx. 0.88 |
| EV/EBITDA Ratio | N/A |
| Net Loss (Q3 2024) | $57.8 million |
| Net Loss (9M 2024) | $160.6 million |
| Stock Price High (Last 12 Months) | $30.00 |
| Dividend Yield | 0% |
| Analyst Consensus Rating | Hold |
| Average Price Target | $17.00 |
Key Risks Facing Pliant Therapeutics, Inc. (PLRX)
Key Risks Facing Pliant Therapeutics, Inc.
Overview of Internal and External Risks
The company faces significant internal and external risks that could impact its financial health. Key risks include:
- Industry Competition: The biopharmaceutical industry is highly competitive, with many companies vying for market share. The success of competitors in developing similar products may hinder the company’s market position.
- Regulatory Changes: Changes in regulations can affect the approval process for new drugs. Delays or rejections from regulatory bodies could significantly impact future revenues.
- Market Conditions: Economic downturns or adverse market conditions can limit access to capital and affect the company's ability to fund research and development.
Recent Financial Performance Data
As of September 30, 2024, the company reported a net loss of $57.8 million for the quarter, compared to a net loss of $41.5 million for the same period in 2023. For the nine months ended September 30, 2024, the net loss increased to $160.6 million from $120.2 million in 2023 .
Operational, Financial, or Strategic Risks
The company’s operational risks include:
- Research and Development Expenses: The company incurred research and development expenses of $130.5 million for the nine months ended September 30, 2024, compared to $94.6 million in 2023. This increase is primarily due to costs associated with clinical trials .
- Cash Flow Concerns: As of September 30, 2024, the company had cash, cash equivalents, and short-term investments totaling $406.0 million, which it believes will fund operations for the next 12 months .
- Accumulated Deficit: The accumulated deficit stood at $660.3 million as of September 30, 2024, indicating substantial historical losses .
Mitigation Strategies
To address these risks, the company has implemented several mitigation strategies:
- Funding Strategies: The company entered into an Amended and Restated Loan and Security Agreement to borrow up to $150.0 million, which will help support ongoing operations .
- Operational Efficiency: The company is actively working to streamline operations and reduce costs, particularly in research and development .
- Partnerships and Collaborations: The company aims to establish new collaborations to diversify funding sources and share development costs .
Financial Overview
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $57.8 million | $41.5 million | $16.3 million |
| Accumulated Deficit | $660.3 million | $499.7 million | $160.6 million |
| Cash, Cash Equivalents, Short-term Investments | $406.0 million | $N/A | $N/A |
| Research and Development Expenses | $130.5 million | $94.6 million | $35.9 million |
Future Growth Prospects for Pliant Therapeutics, Inc. (PLRX)
Future Growth Prospects for Pliant Therapeutics, Inc.
Analysis of Key Growth Drivers
Key growth drivers for the company include advancements in product innovations, market expansions, and strategic partnerships. The company has been focusing on developing novel therapies specifically targeting fibrosis.
Product Innovations
The company is advancing its pipeline with several product candidates. The Phase 1 trial of PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, is currently ongoing. This drug targets TGF-β activation in the tumor microenvironment, and preliminary data is expected in early 2025.
Market Expansions
In 2024, the company aims to expand its operational capabilities and enhance its research and development activities. As of September 30, 2024, the company had cash, cash equivalents, and short-term investments amounting to $406.0 million, which it plans to utilize to support ongoing and future clinical trials.
Future Revenue Growth Projections and Earnings Estimates
Revenue remains a challenge as the company has not generated any revenue from product sales. The termination of the Novartis Agreement resulted in a decrease of $1.58 million in revenue for the nine months ended September 30, 2024, compared to the same period in 2023. Future earnings estimates are expected to be impacted by ongoing research and development expenses, which are projected to increase significantly due to the advancement of product candidates.
Strategic Initiatives or Partnerships
The company is actively seeking new collaborations to bolster its research efforts. The recent Amended Loan Agreement entered in March 2024 allows for up to $150.0 million in non-dilutive capital. This financial flexibility may facilitate new strategic partnerships or collaborations moving forward.
Competitive Advantages
The company's competitive edge lies in its strong intellectual property portfolio and its focus on innovative therapies. As of September 30, 2024, the total stockholders' equity stood at $345.8 million, which reflects the company's robust financial position despite its ongoing losses. Furthermore, the company's commitment to expanding its research capabilities and advancing its clinical trials positions it favorably in the biopharmaceutical landscape.
| Financial Metrics | As of September 30, 2024 | As of December 31, 2023 |
|---|---|---|
| Cash, Cash Equivalents, and Short-term Investments | $406.0 million | $512.2 million |
| Net Loss (Nine Months) | $(160.6 million) | $(120.2 million) |
| Total Stockholders' Equity | $345.8 million | $473.6 million |
| Research and Development Expenses (Nine Months) | $(130.5 million) | $(94.6 million) |
| General and Administrative Expenses (Nine Months) | $(44.5 million) | $(44.1 million) |
Pliant Therapeutics, Inc. (PLRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Pliant Therapeutics, Inc. (PLRX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Pliant Therapeutics, Inc. (PLRX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Pliant Therapeutics, Inc. (PLRX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.